The evolution of Urban C. difficile infection (CDI): CDI in 2009-2011 Is less severe and has better outcomes Than CDI in 2006-2008

American Journal of Gastroenterology

Volumn 109, Issue 8, 2014, Pages 1265-1276

  Feuerstadt, Paul ^a,b   Das, Rohit ^c,d   Brandt, Lawrence J ^e  

^a Gastroenterology Center of Connecticut   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; NEW YORK CITY; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URBAN POPULATION;

EID: 84905595601     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.167     Document Type: Article

References (36)

1. Kyne L, Hamel MB, Polavaram R et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34 : 346-53.
2. Dubberke ER, Reske KA, Olsen MA et al. Short-and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 46 : 497-504.
3. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330 : 257-62.
4. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145 : 758-64.
5. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359 : 1932-40.
6. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171 : 466-72.
7. Daniels KR, Lee GC, Frei CR. The rise in Clostridium difficile infections in United States hospitals, 2001 to 2010. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy (Denver, CO). Arlington, Virginia: Infectious Disease Society of America, 2013: p Abstract K-327.
8. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40 : 1591-7.
9. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353 : 2433-41.
10. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fl uoroquinolone use. Infect Control Hosp Epidemiol 2005; 26 : 273-80.
11. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173 : 1037-42.
12. Gravel D, Miller M, Simor A et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48 : 568-76.
13. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353 : 2442-9.
14. Kenneally C, Rosini JM, Skrupky LP et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 2007; 132 : 418-24.
15. McGowan AP, Lalayiannis LC, Sarma JB et al. Th irty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. J Hosp Infect 2011; 77 : 11-5.
16. Hensgens MP, Goorhuis A, Dekkers OM et al. All-cause and disease-specifi c mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 2013; 56 : 1108-16.
17. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 : 478-98; quiz 499.
18. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 : 373-83.
19. McDonald LC, Coignard B, Dubberke E et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28 : 140-5.
20. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31 : 431-55.
21. Janarthanan S, Ditah I, Adler DG et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107 : 1001-10.
22. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012; 46 : 397-400.
23. Pepin J, Saheb N, Coulombe MA et al. Emergence of fl uoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41 : 1254-60.
24. Dubberke ER, Reske KA, Yan Y et al. Clostridium difficile-associated disease in a setting of endemicity: identifi cation of novel risk factors. Clin Infect Dis 2007; 45 : 1543-9.
25. Stevens V, Dumyati G, Fine LS et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53 : 42-8.
26. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol 2010; 105 : 2040-9.
27. Debast SB, Bauer MP, Kuijper EJ et al. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (Suppl 2) : 1-26.
28. Pepin J, Valiquette L, Gagnon S et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102 : 2781-8.
29. Bauer MP, Notermans DW, van Benthem BH et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377 : 63-73.
30. Manek K, Williams V, Callery S et al. Reducing the risk of severe complications among patients with Clostridium difficile infection. Can J Gastroenterol 2011; 25 : 368-72.
31. Shivashankar R, Khanna S, Kammer PP et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11 : 1466-71.
32. Bloomfield MG, Carmichael AJ, Gkrania-Klotsas E. Mortality in Clostridium difficile infection: a prospective analysis of risk predictors. Eur J Gastroenterol Hepatol 2013; 25 : 700-5.
33. Jardin CG, Palmer HR, Shah DN et al. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect 2013; 85 : 28-32.
34. Micek ST, Schramm G, Morrow L et al. Clostridium difficile infection: a multicenter study of epidemiology and outcomes in mechanically ventilated patients. Crit Care Med 2013; 41 : 1968-75.
35. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97 : 1769-75.
36. Lucado J, Elixhauser A. C. Difficile Infection in Hospital Stays, 2009, Healthcare Cost and Utilization Project 2012, 1-12.